-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Biomarin Pharmaceutical Inc annual Deferred Federal Income Tax Expense (Benefit) history and growth rate from 2010 to 2023.
- Biomarin Pharmaceutical Inc annual Deferred Federal Income Tax Expense (Benefit) for 2023 was -$70.8 M, a 10.7% increase from 2022.
- Biomarin Pharmaceutical Inc annual Deferred Federal Income Tax Expense (Benefit) for 2022 was -$79.3 M, a 165% decline from 2021.
- Biomarin Pharmaceutical Inc annual Deferred Federal Income Tax Expense (Benefit) for 2021 was -$29.9 M, a 35.2% increase from 2020.
Deferred Federal Income Tax Expense (Benefit), Annual Data (USD)